Dexcom · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← DXCM

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q3	2026-09-30	1.34	+11.2%	64.3%	0.33	0.28	20.5%	0.27	0.72	0.40	—
FY2026 Q2	2026-06-30	1.31	+13.1%	63.4%	0.32	0.25	19.0%	0.18	0.64	—	—
FY2026 Q1	2026-03-31	1.19	+15.0%	62.9%	0.26	0.20	16.7%	0.45	0.51	—	—
FY2025 Q4	2025-12-31	1.26	+13.1%	62.9%	0.32	0.27	21.2%	0.19	0.67	0.31	—
FY2025 Q3	2025-09-30	1.21	+21.6%	60.5%	0.24	0.28	23.5%	0.58	0.70	0.19	—
FY2025 Q2	2025-06-30	1.16	+15.2%	59.5%	0.21	0.18	15.5%	0.21	0.45	—	—
FY2025 Q1	2025-03-31	1.04	+12.5%	56.9%	0.13	0.11	10.2%	0.10	0.27	—	—
FY2024 Q4	2024-12-31	1.11	+7.6%	58.9%	0.19	0.15	13.6%	0.18	0.37	0.00	—
FY2024 Q3	2024-09-30	0.99	+2.0%	59.7%	0.15	0.13	13.5%	0.09	0.34	0.75	—
FY2024 Q2	2024-06-30	1.00	+15.3%	62.4%	0.16	0.14	14.3%	0.21	0.35	—	—
FY2024 Q1	2024-03-31	0.92	+24.2%	61.0%	0.10	0.15	15.9%	0.15	0.36	—	—
FY2023 Q4	2023-12-31	1.03	+26.9%	63.5%	0.22	0.26	24.8%	0.08	0.61	0.50	—
FY2023 Q3	2023-09-30	0.98	—	63.9%	0.21	0.12	12.4%	0.22	0.29	0.00	—
FY2023 Q2	2023-06-30	0.87	—	62.7%	0.13	0.12	13.3%	0.13	0.28	—	—
FY2023 Q1	2023-03-31	0.74	—	62.4%	0.05	0.05	6.6%	0.08	0.12	—	—
FY2022 Q4	2022-12-31	0.82	—	66.4%	0.13	0.09	11.3%	0.07	0.23	0.00	—

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.